secwatch.observer — SEC 8-K summary
======================================

Issuer:     SELLAS Life Sciences Group, Inc. (SLS)
CIK:        0001390478
Form:       8-K
Filed at:   2026-06-18T20:30:36+00:00
Accession:  0001104659-26-075775
Event type: other_material
Sentiment:  neutral
Materiality: 0.15
Item codes: 5.07
LLM model:  deepseek-v4-flash:cloud@v2

SELLAS stockholders approve 20M share equity plan increase, re-elect directors
------------------------------------------------------------------------------

- Directors Robert Van Nostrand and Jane Wasman re-elected; Van Nostrand 66.5M for, Wasman 65.9M for.
- Ratification of Baker Tilly US as independent auditor for FY2026 approved with 112.1M votes for.
- Amendment to 2023 Equity Plan increasing authorized shares by 20M approved: 42.9M for, 27.3M against.
- Non-binding advisory say-on-pay resolution passed: 52.9M for, 15.9M against.
- Adjournment proposal approved with 90.6M for, 22.2M against.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1390478/000110465926075775/0001104659-26-075775-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1390478/000110465926075775/tm2618311d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-075775

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer